Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

In development
Reference number: GID-TA11254
Expected publication date: 04 March 2026

Documents

Documents created during the development process.

Invitation to participate

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 227 KB)

Published:

13 May 2025
Equality impact assessment (scoping) (PDF 103 KB)

Published:

13 May 2025
Final stakeholder list (PDF 135 KB)

Published:

13 May 2025
Final scope (PDF 126 KB)

Published:

13 May 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6249

Draft scope post referral (PDF 106 KB)

Published:

17 March 2025
Draft matrix post referral (PDF 98 KB)

Published:

17 March 2025